Use of anti‐CMV immunoglobulins in lung transplant recipients: The French experience

Rational Pending the authorization of new anti‐CMV drugs with fewer adverse effects, exploring the possibilities offered by CMV immunoglobulins (CMVIG) seems necessary. In France, access to CMVIG requires official authorization by the national Health authority and is restricted to second line rescue...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Transplant infectious disease 2021-12, Vol.23 (6), p.e13754-n/a
Hauptverfasser:	Charlotte, Roy, François, Parquin, Jonathan, Messika, Véronique, Boussaud, Olivier, Brugière, Tristan, Degot, Séverine, Feuillet, Jérôme, Lepavec, Adrien, Tissot, Claire, Dromer, Espérie, Burnet, Eve, Camps, Antoine, Roux
Format:	Artikel
Sprache:	eng
Schlagworte:	alternative therapeutics Anaphylaxis Antiviral agents Antiviral Agents - adverse effects CMV CMVIG Cytomegalovirus Cytomegalovirus Infections - drug therapy Cytomegalovirus Infections - prevention & control Health services hematological toxicity Humans Immunoglobulins Immunoglobulins - therapeutic use Immunoglobulins, Intravenous - adverse effects Immunological tolerance Indication Infections Life Sciences Lung lung transplant, rescue treatment Lung transplantation Lung Transplantation - adverse effects Lung transplants Lungs Patients Prophylaxis Pruritus Retrospective Studies Side effects Signs and symptoms Transplant Recipients
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!